Table 6.

Reasons to consider initiating therapy with a dopamine agonist

Reduced motor complications compared with levodopa
Antiparkinsonian effect superior to placebo in early-stage PD
Antiparkinsonian effect comparable to levodopa in early-stage PD
Patients may be able to be maintained on dopamine agonist monotherapy for several years
Supplementation with levodopa provides clinical benefits comparable to levodopa alone but with reduced motor complications
Putative neuroprotective effects